848 related articles for article (PubMed ID: 19673602)
1. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
[TBL] [Abstract][Full Text] [Related]
3. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
[TBL] [Abstract][Full Text] [Related]
5. OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.
McBurnett K; Starr HL
Expert Opin Pharmacother; 2011 Feb; 12(2):315-24. PubMed ID: 21226641
[TBL] [Abstract][Full Text] [Related]
6. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
7. Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD.
Robison RJ; Reimherr FW; Gale PD; Marchant BK; Williams ED; Soni P; Halls C; Strong RE
Ann Clin Psychiatry; 2010 May; 22(2):94-102. PubMed ID: 20445836
[TBL] [Abstract][Full Text] [Related]
8. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
9. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
10. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB
Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519
[TBL] [Abstract][Full Text] [Related]
11. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
12. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.
Wilens T; Pelham W; Stein M; Conners CK; Abikoff H; Atkins M; August G; Greenhill L; McBurnett K; Palumbo D; Swanson J; Wolraich M
J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):424-33. PubMed ID: 12649629
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
14. Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD.
Abikoff H; Nissley-Tsiopinis J; Gallagher R; Zambenedetti M; Seyffert M; Boorady R; McCarthy J
J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):166-75. PubMed ID: 19127171
[TBL] [Abstract][Full Text] [Related]
15. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children].
Pan XX; Ma HW; Wan B; Dai XM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Aug; 10(4):471-4. PubMed ID: 18706164
[TBL] [Abstract][Full Text] [Related]
18. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.
Patrick KS; González MA; Straughn AB; Markowitz JS
Expert Opin Drug Deliv; 2005 Jan; 2(1):121-43. PubMed ID: 16296740
[TBL] [Abstract][Full Text] [Related]
19. Stimulant dosing for children with ADHD: a medical claims analysis.
Olfson M; Marcus S; Wan G
J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):51-9. PubMed ID: 19218896
[TBL] [Abstract][Full Text] [Related]
20. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study.
Cox DJ; Merkel RL; Penberthy JK; Kovatchev B; Hankin CS
J Am Acad Child Adolesc Psychiatry; 2004 Mar; 43(3):269-75. PubMed ID: 15076259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
